Lenacapavir

Lenacapavir (GS-6207) is a HIV-1 capsid inhibitor. Lenacapavir shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs) [1]. Lenacapavir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[2189684-44-2]

Product Name Alternative

GS-6207

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gs-6207.html

Concentration

10mM

Purity

98.44

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

FC1=CC(F)=CC(C[C@@H](C2=NC(C#CC(S(=O)(C)=O)(C)C)=CC=C2C3=CC=C(Cl)C4=C3N(CC(F)(F)F)N=C4NS(=O)(C)=O)NC(CN5C(C(F)(F)[C@@]6([H])[C@]7([H])C6)=C7C(C(F)(F)F)=N5)=O)=C1

Molecular Formula

C39H32ClF10N7O5S2

Molecular Weight

968.28

Precautions

H315, H319, H320

References & Citations

[1]Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227.|[2]John O Link, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Jul 1.